Key Highlights

  • Kala Bio entered a non-binding Letter of Intent with Virotek.
  • The LOI establishes an exclusive U.S. distribution and reseller partnership.
  • The arrangement covers Virotek's ophthalmic genetic screening and diagnostic tests.
  • Final terms remain subject to negotiation of a definitive agreement and various regulatory and Nasdaq approvals.

Kala Bio, Inc. (NASDAQ: KALA) entered a non-binding Letter of Intent with Virotek to establish an exclusive U.S. distribution and reseller Partnership for Virotek's ophthalmic genetic screening and diagnostic tests.

What Happened

While the arrangement offers a potential path for commercial portfolio growth, final terms remain subject to the negotiation and execution of a definitive agreement and various corporate, regulatory, and Nasdaq approvals.

Market Reaction

The disclosed information does not include stock price or trading data for Kala Bio following the Letter of Intent announcement.

Outlook

Negotiation and execution of a definitive agreement, along with the required corporate, regulatory, and Nasdaq approvals, represent the next steps before this partnership can be finalized.